Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Anxiety, depression and impaired health-related quality of life are therapeutic challenges in patients with multiple sclerosis.
Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approach.
[The specialised MS networks, at the heart of the organisation of patient paths].
Current role of chemotherapy and bone marrow transplantation in multiple sclerosis.
Assessing relapse in multiple sclerosis questionnaire: results of a pilot study.
Association of interleukin (IL)-4 gene intron 3 VNTR polymorphism with multiple sclerosis in Turkish population.
Opening locked doors: Integrating a palliative care approach into the management of patients with severe multiple sclerosis.
Erratum: microRNA dysregulation in multiple sclerosis.
Clinical response and tolerability of fampridine in clinical practice.
Mechanisms of Oxidative Damage in Multiple Sclerosis and Neurodegenerative Diseases: Therapeutic Modulation via Fumaric Acid Esters.
Implanting glass spinal cord windows in adult mice with experimental autoimmune encephalomyelitis.
Symptomatic treatment and management of multiple sclerosis.
Repair strategies for multiple sclerosis: challenges, achievements and perspectives.
Towards an endophenotype in multiple sclerosis.
Prevalence of overweight, obesity and metabolic syndrome components in multiple sclerosis patients with significant disability.
Utilized Resources of Hope, Orientation, and Inspiration in Life of Persons with Multiple Sclerosis and Their Association with Life Satisfaction, Adaptive Coping Strategies, and Spirituality.
Multimodal Therapy of Recurrent Severe Acute Disseminated Encephalomyelitis: The Role of Immunoadsorption.
Association of Deep Gray Matter Damage With Cortical and Spinal Cord Degeneration in Primary Progressive Multiple Sclerosis.
Patterns and predictors of naturally occurring change in depressive symptoms over a 30-month period in multiple sclerosis.
Current and future potential of retinal optical coherence tomography in multiple sclerosis with and without optic neuritis.
Nutrients, Microglia Aging, and Brain Aging.
Immune surveillance of the central nervous system in multiple sclerosis - Relevance for therapy and experimental models.
The physical anthropometry, lifestyle habits and blood pressure of people presenting with a first clinical demyelinating event compared to controls: The Ausimmune study.
Inhibitory effect of matrine on blood-brain barrier disruption for the treatment of experimental autoimmune encephalomyelitis.
Functional ionotropic glutamate receptors on peripheral axons and myelin.
Pages
« first
‹ previous
…
523
524
525
526
527
528
529
530
531
…
next ›
last »